ASAAP is a clinical trial evaluating the efficacy, safety, tolerability and pharmacokinetics of a new antimalarial combination drug, with particular focus on its successful application in one of the largest and most vulnerable demographics of Africa – i.e. children 0-10 years old. The overall aim is to develop new antimalarial treatments by combining existing, efficacious medicines for treatment of malaria in African children by promoting African and European research collaboration and strengthening the capacity of African institutions to conduct clinical research.
The project is being led and coordinated by Dr. Oumou Maiga-Ascofaré, representing the KCCR in Kumasi, Ghana under the authority of the Kwame Nkrumah University of Science and Technology (KNUST), in collaboration with:
- Institut de Recherche Clinique du Bénin (IRCB) in Abomey-Calavi in Benin
- Institut des Sciences et Techniques (INSTech) in Bobo-Dioulasso in Burkina Faso
- Centre de Recherches Médicales de Lambaréné (CERMEL) in Lambaréné in Gabon
- Université des Sciences, des Techniques et des Technologies de Bamako (USTTB) in Bamako in Mali
- Institut de Recherche pour le Développement (IRD) in Marseille in France
- Bernhard-Nocht-Institut für Tropenmedizin (BNITM) in Hamburg in Germany
- Kwame Nkrumah University of Science & Technology (KNUST) in Kumasi in Ghana
Meaning of Logo
ASAAP is the acronym for Clinical Evaluation of AntimalarialS tri-therapy with AtovAquone-Proguanil for malaria treatment in African children. The antimalarials in use will be artemether-lumefantrine and atovaquone-proguanil. The logo is composed of 3 triangles representing pills that have a triangular shape to symbolise triple-therapy treatment. The mosquito replaces the letter “S” because a large component of the study is focused on malaria parasite transmission. The map of Africa represents the focus of the study on African population and also represents the letter “P” when mirrored. The slogan “Stronger Together” captures the essence of triple therapy and the objective of the study – the combination of drugs for improved treatment through collaborative efforts.
